ARCT-021
Vaccine candidate against COVID-19
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | mRNA |
| Clinical data | |
| Other names | LUNAR-COV19 |
| Routes of administration | Intramuscular |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
| Medical response |
|
 COVID-19 portal |
|
ARCT-021, also known as LUNAR-COV19, is a COVID-19 vaccine candidate developed by Arcturus Therapeutics.
Medical uses
It requires the intramuscular injection with a single dose.[1]
Pharmacology
ARCT-021 is an mRNA vaccine.[2]
History
Arcturus Therapeutics partnered with Singapore's Duke–NUS Medical School to develop a COVID-19 vaccine.[3] The company also partnered with Catalent, a contract development and manufacturing organization, to manufacture multiple batches of Arcturus' COVID-19 mRNA vaccine candidate.[4]
Clinical trials
LUNAR-COV19 clinical trials in humans began in July 2020.[5] On 4 January 2021, Arcturus Therapeutics started Phase-2 clinical trials.[6]
Economics
Arcturus has entered into development and supply agreements with the Economic Development Board of Singapore and supply agreements with the Israel Ministry of Health for LUNAR-COV19.[7][8]
References
- ^ "Arcturus Therapeutics Announces First Quarter 2021 Company Overview and Financial Results and Provides New Clinical Data". Businesswire. 10 May 2021. Retrieved 9 September 2021.
- ^ "Arcturus Therapeutics Announces that it has Initiated Dosing of its COVID-19 STARR mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in a Phase 1/2 study". Globe Newswire. 11 August 2020.
- ^ Teo J (15 April 2020). "Coronavirus: Clinical trials for Singapore's vaccine project could start in August". The Straits Times. Retrieved 27 April 2020.
- ^ Stanton D (6 May 2020). "With Arcturus, Catalent bags another COVID project". Bioprocess Insider. Retrieved 8 May 2020.
- ^ Clinical trial number NCT04480957 for "Phase 1/2 Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects" at ClinicalTrials.gov
- ^ "Arcturus Therapeutics Receives FDA Allowance to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate in the". Bloomberg. 4 January 2021. Retrieved 17 January 2021.
- ^ Anwar N (26 November 2020). "Singapore's co-developed vaccine candidate is in 'good shape' for delivery in 2021". CNBC. Retrieved 18 March 2021.
- ^ Cheok M, Mookerjee I (5 August 2020). "Singapore Will Get First Claim to Any Successful Arcturus Vaccine". Bloomberg. Retrieved 18 March 2021.
External links
Scholia has a profile for Lunar-COV19 (Q98713328).
Portals:
Medicine
Viruses
COVID-19
 | This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
 | This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
